Intraoperative cell salvage vs transfusion in ovarian cancer
ISRCTN | ISRCTN19517317 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN19517317 |
Secondary identifying numbers | 31586 |
- Submission date
- 07/11/2016
- Registration date
- 11/11/2016
- Last edited
- 22/05/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Contact information
Public
Peninsula Clinical Trials Unit
N16, ITTC Building 1
Plymouth Science Park
Plymouth
PL6 8BX
United Kingdom
Phone | +44 (0)1752 315250 |
---|---|
jane.vickery@plymouth.ac.uk |
Study information
Study design | Randomised; Interventional; Design type: Treatment, Process of Care, Management of Care, Surgery |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | A randomised controlled feasibility Trial of Intraoperative Cell salvage vs donor blood Transfusion in Ovarian Cancer surgery (TICTOC) |
Study acronym | TICTOC |
Study objectives | The aim of this study is to test the processes for a larger definitive trial, ascertain its feasibility and provide the necessary information to plan a full trial, assessing the clinical and cost effectiveness of intra-operative cells salvage for women undergoing surgery for ovarian cancer, compared with the usual practice of transfusing donor blood. |
Ethics approval(s) | South West - Exeter Research Ethics Committee, 14/10/2016, ref: 16/SW/0256 |
Health condition(s) or problem(s) studied | Specialty: Cancer, Primary sub-specialty: Gynae; UKCRC code/ Disease: Cancer/ Malignant neoplasms of female genital organs |
Intervention | Sixty participants will be randomised in a 1:1 ratio to intraoperative cell salvage (ICS, re-infusion of their own blood) or donor blood transfusion during surgery. Participants and outcome assessors will be blinded to the intervention. For all participants the standard operative procedure for ovarian cancer (cytoreductive surgery) will be performed. If intraoperative transfusion is required, the participant will receive either ICS or donor transfusion according to treatment allocation. Some participants may not require any intraoperative transfusion and some (either arm of the trial) may require donor blood transfusion post-operatively. Intra-operative cell salvage arm: The cell salvage system to be used in this study is the Haemonetics Cell Saver® 5+ autologous blood recovery system. All sites will follow a common ICS protocol. Collected blood will be processed using a 125ml bowl before being re-infused via a leucodepletion filter. All full bowls of salvaged blood will be reinfused back to the participant during, or at the end of, the operative procedure. ICS blood will be returned even if only small quantities are lost. Participants allocated to the ICS arm who also need donor transfusion for clinical reasons can be given donor blood at any time, during or after surgery, for the duration of their hospital stay. Donor transfusion arm: Participants allocated to donor transfusion will be considered for intraoperative transfusion in accordance with clinical judgement, guided by local hospital policy. Donor blood transfusion may also be given post-operatively in accordance with usual clinical care. Donor blood will only be given (in standard volumes) when deemed necessary (e.g. after substantial blood loss and/or drop in haemoglobin). Trial treatment is confined to the intra-operative period only. All participants will be followed up at 30 days post-operatively, by telephone, for adverse events reporting and 6 weeks and 3 months post-operatively by post. In addition, participants recruited in the early part of the study will be followed up by post at subsequent three month intervals (at 6 and 9 months) as time allows. |
Intervention type | Other |
Primary outcome measure | Feasibility outcomes: 1. Recruitment rate is recorded as the number of eligible participants who consent to participate in the study by 12 months 2. Feasibility of randomisation immediately pre-operatively is recorded by the time interval between randomisation and beginning of surgery 3. Attrition rate is recorded as the number of participants who consent to participate that remain in the study until the end of follow up at three months 4. Completeness of proposed outcome measures will be recorded as the number of complete specific data fields within CRFs and patient questionnaire booklets received at end of follow up at three months, out of the expected total number of CRFs and booklets 5. Success of blinding of allocation for participants and outcome assessor will be recorded by the number of participants and assessors who are inadvertently made aware of their treatment allocation during the trial period 6. Success of data collection tools and methods to collect resource use data will be recorded as the proportion of completed resource use data fields available at end of follow-up 7. Acceptability of the intervention to participants will be assessed by qualitative interviews 8. Acceptability of study participation to participants will be assessed by qualitative interviews |
Secondary outcome measures | No secondary outcome measures |
Overall study start date | 01/07/2016 |
Completion date | 30/06/2018 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Female |
Target number of participants | Planned Sample Size: 60; UK Sample Size: 60 |
Total final enrolment | 57 |
Key inclusion criteria | 1. 18 years old or over 2. Suspected or confirmed ovarian cancer (newly diagnosed) requiring cytoreductive surgery, whether primary or interval (following chemotherapy) 3. CT scan evidence (with or without clinical evidence) compatible with FIGO stage III/IV ovarian cancer/ primary peritoneal cancer at presentation* 4. ECOG Performance Status 0-1 5. Willing to participate and able to give written informed consent *CT features of pelvic mass (or features suggestive of primary peritoneal cancer) and extrapelvic involvement including ascites, omental disease, peritoneal thickening, bowel surface and/or mesentery involvement, enlarged pelvic and para-aortic lymph nodes, evidence of disease on diaphragm |
Key exclusion criteria | 1. Diagnosis of concurrent malignancy 2. Pregnant 3. Donor transfusion during the week prior to surgery 4. Haemoglobinopathies (e.g. sickle cell, thalassaemia) 5. Unwilling to accept donor blood (e.g. on religious grounds) |
Date of first enrolment | 17/01/2017 |
Date of final enrolment | 28/02/2018 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Treliske
Truro
TR1 3LJ
United Kingdom
Plymouth
PL6 8DH
United Kingdom
Sheriff Hill
Gateshead
NE9 6SX
United Kingdom
Sponsor information
Hospital/treatment centre
Research, Development & Innovation Manager
Knowledge Spa
Royal Cornwall Hospitals NHS Trust
Truro
TR1 3LJ
England
United Kingdom
https://ror.org/026xdcm93 |
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
Results and Publications
Intention to publish date | 31/12/2018 |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Data sharing statement to be made available at a later date |
Publication and dissemination plan | The study team will prepare a plain English summary of the study results which will be made available to study participants as soon as possible after the end of the study (June 2018). The final results of the study will be disseminated via presentations at appropriate scientific meetings and conferences and publication in appropriate peer-reviewed journals. Indicative publication date end 2018. |
IPD sharing plan | The current data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Protocol article | protocol | 01/11/2018 | 01/11/2019 | Yes | No |
Plain English results | 22/05/2023 | No | Yes | ||
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
22/05/2023: Cancer Research UK plain English results link and total final enrolment added.
01/11/2019: Publication reference added.
19/04/2018: The recruitment start date was changed from 01/11/2016 to 17/01/2017.
12/02/2018: The recruitment end date was changed from 31/01/2018 to 28/02/2018.
02/11/2017: The recruitment end date was changed from 31/10/2017 to 31/01/2018.
06/06/2017: Cancer Help UK lay summary link added to plain English summary field